Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 82 of 102, showing 5 Applications out of 510 total, starting on record 406, ending on 410

# Protocol No Study Title Investigator(s) & Site(s)

406.

ECCT/15/12/05   Post-discharge Malaria Chemoprevention(PMC) study
    Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial   
Principal Investigator(s)
1. Titus Kwambai
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Migori County Referral Hospital (Migori county)
4. Busia County Referral Hospital (Busia county)
 
View

407.

ECCT/15/10/04   AZM
    Azithromycin (AZM) to prevent post-discharge    morbidity and mortality in Kenyan children   
Principal Investigator(s)
1. Judd Walson Walson
Site(s) in Kenya
1. Homa Bay County referral Hospital (Homa Bay county)
2. Kisii Teaching and referral Hospital (Kisii county)
 
View

408.

ECCT/15/11/05   FALCI Study
    A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria.   
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
1. KEMRI Center for Respiratory Diseases Research (Siaya county)
2. KEMRI Walter Reed Kombewa (Kisumu county)
3. KEMRI Kisumu (Kisumu county)
 
View

409.

ECCT/15/11/04   VAC040
    A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months)   
Principal Investigator(s)
1. John Anthony Gerard Scott
Site(s) in Kenya
KEMRI-Wellcome Trust Research Program
 
View

410.

ECCT/15/08/01   Rifapentine During Intensive Phase TB Treatment
     Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial   
Principal Investigator(s)
1. Elisha Ochieng Okeyo
Site(s) in Kenya
KEMRICDC, KISUMU, KENYA
 
View